910 related articles for article (PubMed ID: 18840377)
1. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
2. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
3. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland.
Delcò F; Egger R; Bauerfeind P; Beglinger C
Aliment Pharmacol Ther; 2005 Mar; 21(5):615-22. PubMed ID: 15740546
[TBL] [Abstract][Full Text] [Related]
4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
5. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
6. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
8. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
9. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
Kobelt-Nguyen G; Gerdtham UG; Alm A
J Glaucoma; 1998 Apr; 7(2):95-104. PubMed ID: 9559495
[TBL] [Abstract][Full Text] [Related]
10. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
Stäbler W; Wagner B
Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
[TBL] [Abstract][Full Text] [Related]
11. Second-line and third-line chemotherapy for lung cancer: use and cost.
Ramsey SD; Martins RG; Blough DK; Tock LS; Lubeck D; Reyes CM
Am J Manag Care; 2008 May; 14(5):297-306. PubMed ID: 18471034
[TBL] [Abstract][Full Text] [Related]
12. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.
Ringborg A; Martinell M; Stålhammar J; Yin DD; Lindgren P
Int J Clin Pract; 2008 May; 62(5):708-16. PubMed ID: 18355236
[TBL] [Abstract][Full Text] [Related]
13. Costs associated with resource utilization during the palliative phase of care: a Canadian perspective.
Dumont S; Jacobs P; Fassbender K; Anderson D; Turcotte V; Harel F
Palliat Med; 2009 Dec; 23(8):708-17. PubMed ID: 19837702
[TBL] [Abstract][Full Text] [Related]
14. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
van Agthoven M; Segeren CM; Buijt I; Uyl-de Groot CA; van der Holt B; Lokhorst HM; Sonneveld P
Eur J Cancer; 2004 May; 40(8):1159-69. PubMed ID: 15110879
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
19. Resource use and costs associated with different states of breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Int J Technol Assess Health Care; 2007; 23(2):223-31. PubMed ID: 17493308
[TBL] [Abstract][Full Text] [Related]
20. Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ; Scuffham PA; McCollam PL; Newby DE
Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
